.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Baxter
UBS
AstraZeneca
Moodys
Dow
Fuji
Colorcon
Novartis
Cerilliant

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,960,577

« Back to Dashboard

Which drugs does patent 6,960,577 protect, and when does it expire?


Patent 6,960,577 protects PROZAC, SYMBYAX, ZYPREXA ZYDIS, and ZYPREXA, and is included in four NDAs. There have been two Paragraph IV challenges on Symbyax.

This patent has twenty-six patent family members in twenty-three countries.

Summary for Patent: 6,960,577

Title: Combination therapy for treatment of refractory depression
Abstract:Methods for treating a patient suffering from or susceptible to treatment resistant major depression comprising administering olanzapine and fluoxetine are disclosed.
Inventor(s): Tollefson; Gary Dennis (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:10/144,159
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eli Lilly And CoPROZACfluoxetine hydrochlorideCAPSULE;ORAL018936-006Dec 23, 1992AB1RXYesNo► Subscribe► SubscribePROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS► Subscribe
Eli Lilly And CoPROZACfluoxetine hydrochlorideCAPSULE;ORAL018936-001Dec 29, 1987AB1RXYesNo► Subscribe► SubscribePROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS► Subscribe
Eli Lilly And CoPROZACfluoxetine hydrochlorideCAPSULE;ORAL018936-003Jun 15, 1999ABRXYesYes► Subscribe► SubscribePROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS► Subscribe
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-001Apr 9, 2007ABRXYesNo► Subscribe► SubscribeSYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS► Subscribe
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-002Dec 24, 2003ABRXYesNo► Subscribe► SubscribeSYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS► Subscribe
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-004Dec 24, 2003ABRXYesNo► Subscribe► SubscribeSYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS► Subscribe
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-003Dec 24, 2003ABRXYesYes► Subscribe► SubscribeSYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS► Subscribe
LillySYMBYAXfluoxetine hydrochloride; olanzapineCAPSULE;ORAL021520-005Dec 24, 2003ABRXYesNo► Subscribe► SubscribeSYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS► Subscribe
LillyZYPREXA ZYDISolanzapineTABLET, ORALLY DISINTEGRATING;ORAL021086-001Apr 6, 2000ABRXYesYes► Subscribe► SubscribeZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS► Subscribe
LillyZYPREXA ZYDISolanzapineTABLET, ORALLY DISINTEGRATING;ORAL021086-002Apr 6, 2000ABRXYesNo► Subscribe► SubscribeZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,960,577

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Indonesia26861► Subscribe
Israel139592► Subscribe
Hungary0101901► Subscribe
Hong Kong1040055► Subscribe
CroatiaP20000797► Subscribe
European Patent Office0958824► Subscribe
Eurasian Patent Organization200001218► Subscribe
Japan2002516282► Subscribe
Malaysia127938► Subscribe
Norway20005885► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Argus Health
Accenture
Harvard Business School
Farmers Insurance
Queensland Health
Cipla
Fish and Richardson
Deloitte
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot